<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ucb Sa — News on 6ix</title>
    <link>https://6ix.com/company/ucb-sa</link>
    <description>Latest news and press releases for Ucb Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 27 Mar 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ucb-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683619e978dffbe2df13e8ec.webp</url>
      <title>Ucb Sa</title>
      <link>https://6ix.com/company/ucb-sa</link>
    </image>
    <item>
      <title>UCB - Convening Notice to the General Meeting of the Shareholders 2026</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-convening-notice-to-the-general-meeting-of-the-shareholders-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-convening-notice-to-the-general-meeting-of-the-shareholders-2026-1</guid>
      <pubDate>Fri, 27 Mar 2026 06:00:00 GMT</pubDate>
      <description>CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the general meeting of the shareholders (the “General Meeting”) which will be held on Thursday, 30 April 2026, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at the end of this convening notice. Shareh</description>
    </item>
    <item>
      <title>Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care</title>
      <link>https://6ix.com/company/ucb-sa/news/gen-z-millennial-patients-chronic-120000317</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/gen-z-millennial-patients-chronic-120000317</guid>
      <pubDate>Wed, 10 Sep 2025 12:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today shared results from the &quot;Rheum for Improvement&quot; survey that sought to further understand unmet needs among patients living with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).</description>
    </item>
    <item>
      <title>UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-presents-latest-research-clinical-060000213</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-presents-latest-research-clinical-060000213</guid>
      <pubDate>Fri, 29 Aug 2025 06:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) Congress, Lisbon, Portugal, August 30 – September 3, 2025. Data will focus on developmental and epileptic encephalopathies (DEEs), such as Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), as well as prolonged seizures, seizure emergencies and early pipeline research.</description>
    </item>
    <item>
      <title>UCB&apos;s HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment</title>
      <link>https://6ix.com/company/ucb-sa/news/ucbs-hs-summit-united-patients-120000513</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucbs-hs-summit-united-patients-120000513</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion about HS, a dermatologic disease that remains both underdiagnosed and often misdiagnosed.2-3 By bringing stakeholders together, UCB sought to foster a deeper understanding of HS and address the challenges associated with it.</description>
    </item>
    <item>
      <title>UCB extends its BIMZELX® &quot;Get Yourself Back&quot; direct-to-consumer campaign for the hidradenitis suppurativa community</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-extends-bimzelx-yourself-back-110000366</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-extends-bimzelx-yourself-back-110000366</guid>
      <pubDate>Tue, 08 Jul 2025 11:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced the expansion of its &quot;Get Yourself Back&quot; direct-to-consumer (DTC) advertising campaign for BIMZELX® (bimekizumab-bkzx). This campaign aims to raise awareness of BIMZELX and offers educational resources about both BIMZELX and hidradenitis suppurativa (HS), encouraging people living with the disease to talk with their healthcare provider about whether BIMZELX is right for them. BIMZELX is the first and only approved treatment for adults with</description>
    </item>
    <item>
      <title>UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-announces-positive-results-gemz-110000092</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-announces-positive-results-gemz-110000092</guid>
      <pubDate>Fri, 27 Jun 2025 11:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and most key secondary endpoints.3 The study is a randomized, double-blind, placebo-controlled, fixed-dose, multi-center study examining the efficacy and safety of adjunctive fenfluramine treatment in 87 individuals aged one through 35, with a CDD diagnosis and uncontrolled seizures.4</description>
    </item>
    <item>
      <title>UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-presents-latest-thymidine-kinase-110000567</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-presents-latest-thymidine-kinase-110000567</guid>
      <pubDate>Fri, 20 Jun 2025 11:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, announced it will present pioneering TK2d research at the UMDF Mitochondrial Medicine 2025 Conference taking place June 18-21, 2025, in St. Louis, Missouri.</description>
    </item>
    <item>
      <title>Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.</title>
      <link>https://6ix.com/company/ucb-sa/news/inaugural-2025-ucb-u-myasthenia-122200664</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/inaugural-2025-ucb-u-myasthenia-122200664</guid>
      <pubDate>Tue, 17 Jun 2025 12:22:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies UCB&apos;s dedication to supporting the rare disease community that goes beyond medicine. Living with or supporting a loved one impacted by this rare disease can be challenging. This scholarship program can help ease the costs associated with education and allow recipients to gain new skills to further their c</description>
    </item>
    <item>
      <title>UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-announces-major-u-investment-163000441</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-announces-major-u-investment-163000441</guid>
      <pubDate>Thu, 12 Jun 2025 16:30:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics manufacturing facility in the United States. The project is expected to serve UCB&apos;s growing number of patients in the U.S., while delivering a total estimated economic impact of approximately $5 billion. UCB is also continuing to scale up its partnerships with U.S. CMOs to ensure the support for the producti</description>
    </item>
    <item>
      <title>Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity</title>
      <link>https://6ix.com/company/ucb-sa/news/dapirolizumab-pegol-phase-3-data-050000876</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/dapirolizumab-pegol-phase-3-data-050000876</guid>
      <pubDate>Thu, 12 Jun 2025 05:00:00 GMT</pubDate>
      <description>Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Eu</description>
    </item>
    <item>
      <title>BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis</title>
      <link>https://6ix.com/company/ucb-sa/news/bimzelx-bimekizumab-bkzx-three-data-161600030</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/bimzelx-bimekizumab-bkzx-three-data-161600030</guid>
      <pubDate>Wed, 11 Jun 2025 16:16:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and ankylosing spondylitits (AS). BIMZELX, a dual inhibitor of IL-17A and IL-17F,1 demonstrated sustained control of inflammat</description>
    </item>
    <item>
      <title>UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-domino-data-lab-collaborate-163000071</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-domino-data-lab-collaborate-163000071</guid>
      <pubDate>Mon, 19 May 2025 16:30:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world&apos;s largest enterprises, today announced a strategic collaboration aimed at modernizing a Statistical Computing Environment (SCE) for the life sciences industry. This joint effort aims to transform the legacy SCE into unified, scalable, and flexible platforms to meet the evolving demands of clinical research, regulatory compliance, and efficient data analysis.</description>
    </item>
    <item>
      <title>UCBJY - Books will close today, April 25, 2025</title>
      <link>https://6ix.com/company/ucb-sa/news/ucbjy-books-will-close-today-april-25-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucbjy-books-will-close-today-april-25-2025</guid>
      <pubDate>Fri, 25 Apr 2025 12:42:31 GMT</pubDate>
      <description>UCBJY - Books will close today, April 25, 2025.</description>
    </item>
    <item>
      <title>UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-presents-latest-research-across-110000212</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-presents-latest-research-across-110000212</guid>
      <pubDate>Thu, 03 Apr 2025 11:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), generalized myasthenia gravis (gMG), and thymidine kinase 2 deficiency (TK2d), at this year&apos;s American Academy of Neurology (AAN) meeting, San Diego, California, April 5-9, 2025.</description>
    </item>
    <item>
      <title>UCB Convening Notice to the General Meeting of the Shareholders 2025</title>
      <link>https://6ix.com/company/ucb-sa/news/ucb-convening-notice-general-meeting-060000008</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/ucb-convening-notice-general-meeting-060000008</guid>
      <pubDate>Fri, 21 Mar 2025 06:00:00 GMT</pubDate>
      <description>CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the ordinary general meeting of the shareholders (the “General Meeting”) which will be held on Thursday, 24 April 2025, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at the end of this convening notic</description>
    </item>
    <item>
      <title>New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference</title>
      <link>https://6ix.com/company/ucb-sa/news/data-investigational-therapy-thymidine-kinase-110000428</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/data-investigational-therapy-thymidine-kinase-110000428</guid>
      <pubDate>Wed, 19 Mar 2025 11:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with thymidine kinase 2 deficiency (TK2d), at this year&apos;s MDA Clinical and Scientific Conference, Dallas, Texas, March 16-19, 2025.</description>
    </item>
    <item>
      <title>Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome</title>
      <link>https://6ix.com/company/ucb-sa/news/epilepsia-publishes-final-analysis-open-175400720</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/epilepsia-publishes-final-analysis-open-175400720</guid>
      <pubDate>Wed, 12 Mar 2025 17:54:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from the final analysis of the long-term open-label extension (OLE) study evaluating the safety and effectiveness of FINTEPLA® (fenfluramine) in patients with Dravet syndrome (DS). Results showed that FINTEPLA was generally well tolerated. The most common treatment-emergent adverse events (TEAEs) were pyrexia, nasopharyngitis and decreased appetite.2 The efficacy analysis showed a statistically significant</description>
    </item>
    <item>
      <title>BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden</title>
      <link>https://6ix.com/company/ucb-sa/news/bimzelx-bimekizumab-bkzx-two-data-130000049</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/bimzelx-bimekizumab-bkzx-two-data-130000049</guid>
      <pubDate>Fri, 07 Mar 2025 13:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only medicine approved to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F),1 continues to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by draining tunnels (</description>
    </item>
    <item>
      <title>BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis</title>
      <link>https://6ix.com/company/ucb-sa/news/bimzelx-bimekizumab-bkzx-five-data-130000473</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/bimzelx-bimekizumab-bkzx-five-data-130000473</guid>
      <pubDate>Fri, 07 Mar 2025 13:00:00 GMT</pubDate>
      <description>UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe plaque psoriasis (PSO). Dual inhibition with BIMZELX demonstrated high efficacy and sustained clinical benefits across different adult patient populations living with this common inflammatory skin condition.1-4</description>
    </item>
    <item>
      <title>On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth</title>
      <link>https://6ix.com/company/ucb-sa/news/growth-path-decade-plus-strong-120000933</link>
      <guid isPermaLink="true">https://6ix.com/company/ucb-sa/news/growth-path-decade-plus-strong-120000933</guid>
      <pubDate>Thu, 27 Feb 2025 12:00:00 GMT</pubDate>
      <description>UCB Full-Year Report 2024, Brussels (Belgium) – regulated information</description>
    </item>
  </channel>
</rss>